

# Taiwan's New Brain Tumor Target-drug "Cerebraca Wafer" Can Prolong Survival Time by up to 250%

*Everfront Biotech is the leading laboratory for cancer drug development in Taiwan, this new drug gives patients new opportunities.*

TAIPEI, TAIWAN, April 10, 2018 /EINPresswire.com/ -- The Cerebraca wafer from Taiwan's [Everfront Biotech](#) Inc., which is used for treating brain tumors, has been approved by the FDA to initiate Phase I/IIa Human Clinical Trials, and the experiment project was conducted by the company in the first half of 2017. On December 25, 2017, the first case of "human trial of a malignant brain glioma tumor relapsed patient using brain cancer targeted therapy" was carried out at Hualien Tzu Chi Hospital in Taiwan. This trial marks a significant advance in the research on malignant brain tumors and reduces their likelihood of relapse through medication. The research on the Cerebraca wafer target drug to treat malignant brain tumors has achieved remarkable results. In recent years, such research has been published in authoritative and world-renowned journals, such as "Journal of Neurochemistry," "Neuro Oncology," "Clinical Cancer Research," "Oncogene," etc., catching the world's attention with regard to cancer drug development programs.

According to statistical reports from the American Cancer Society and the Central Brain Tumor Registry (CBTRUS), an estimated 20,000 new cases of brain tumors are diagnosed each year. Among them, glioblastoma multiforme (GBM) is a kind of malignant brain tumor in which the tumor can grow up to 16 times within 1 month and has a very high relapse rate after resection. In general, patients diagnosed with GBM 4 have an average survival rate of only 12 to 18 months.

The "Cerebraca wafer-based Phase I/IIa human clinical trial to treat malignant brain tumors," which is being jointly implemented by Everfront Biotech and Hualien Tzu Chi Hospital, aims to test the safety and effectiveness of the new drug in humans. To date, they have completed several cases, and future research results are expected to help even more brain tumor patients. The Chairman of Everfront Biotech, Zhou Pei-Wen, pointed out that "Everfront Biotech has simultaneously promoted several new drug development projects, with the Cerebraca wafer already being patented in the United States, the EU, China, Japan, and Taiwan. The clinical trials of this drug for treating brain tumors have brought about revolutionary changes."

The noticeable symptoms of brain tumors may include severe dizziness, headache, nausea, and vomiting, which may even lead to epilepsy, blurred vision, difficulty swallowing, etc. Once relevant neurological symptoms occur, in addition to the possibility of a brain tumor, a cerebrovascular-related disorder may also be diagnosed. In such cases, the patients must go to a medical institution for a detailed examination to determine the root of the problem and treat it as soon as possible.

Chen Jia-Jia  
Everfront Biotech Inc.  
+866-2-2694-0776  
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable

to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.  
© 1995-2019 IPD Group, Inc. All Right Reserved.